During the 14th Five-Year Plan period, China's National Medical Products Administration (NMPA) approved a total of 210 innovative drugs, maintaining a trend of accelerated growth, according to CCTV. In terms of both innovative drug pipelines and the number of clinical trial projects, China ranks among the highest in the worl...